<?xml version="1.0" encoding="UTF-8"?>
<p>The high number of deaths and clinical complications observed in SARS- and MERS-CoV epidemics motivated the search for effective therapeutic agents. This was necessitated when many of the tested conventional drugs and antiviral therapies proved ineffective in treating SARS-CoV infections. For example, the initial treatment of SARS-CoV with antiviral agents such as ribavirin and corticosteroids did not achieve very satisfactory results, mainly because corticosteroids exert immunosuppressor effects on the humoral and cellular immune systems [
 <xref rid="B108" ref-type="bibr">108</xref>, 
 <xref rid="B109" ref-type="bibr">109</xref>]. Other drugs such as pentoxifylline were considered for the treatment of SARS due to its interesting therapeutic properties that include anti-inflammatory, antiviral, immunomodulatory, and bronchodilatory effects. However, it too was not successful in the clinical treatment of SARS-CoV infection [
 <xref rid="B110" ref-type="bibr">110</xref>].
</p>
